Navigation Links
Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal

BRISBANE, Australia, May 29, 2007 /PRNewswire/ -- Phase II results exceed expectations - Alchemia prepares for FDA talks on HyCAMP(TM)

Australian drug development company Alchemia Limited will commence discussions with the US Food and Drug Administration (FDA) following the successful conclusion of the Phase II clinical trial of its metastatic colorectal cancer treatment, HyCAMP(TM).

The final data from the randomized Phase II clinical trial in 80 patients with metastatic colorectal cancer treated with HyCAMP(TM) versus Camptosar(R) shows:


    - HyCAMP(TM) exerted superior anti-cancer activity with a significantly

      greater number of patients with observed tumour responses


    - A statistically significant increase in 'time to treatment failure'

      demonstrating that HyCAMP(TM) patients were able to stay on treatment

      longer due to reduced toxicity and increased efficacy


    - A significantly longer period (+116%) of 'progression-free survival' for

      patients receiving HyCAMP(TM)*


    - Patients on HyCAMP(TM) were able to receive therapy for a median of

      three times longer than those receiving Camptosar(R)*


    - A clinically significant trend towards longer overall survival for

      patients receiving HyCAMP(TM)


    - HyCAMP(TM) patients received less doses of anti-diarrheal medication

      than Camptosar(R) patients


    - This data was announced to the ASX on April 26 2007

Alchemia Chief Executive Officer, Dr Peter Smith said, "The fact that we are seeing statistically significant improvements in efficacy end-points from such a small study is a reflection of the substantial increase in anti-tumour activity seen with HyCAMP(TM). Generally, much larger studies would be required to show such effects. This data is an exceptional validation of our HyACT(TM) drug delivery technology platform and its application to the treatment of cancer
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive Final Data from HyCAMP Phase Trial Metastatic Colorectal
(Date:4/24/2015)... HANOVER, N.J. , April 24, 2015  Novartis Pharmaceuticals ... for the second year in a row on the annual ... results of its 2015 Top 50 Companies for Diversity on ... York, NY . NPC also ranked second on the ... the Top 10 Companies for Employee Resource Groups list. ...
(Date:4/24/2015)... T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), a ... products and a licensed producer ("LP") to cultivate marijuana ... Canada ) ("MMPR"), is pleased to announce that ... the transaction announced on March 11, 2015 with Medna ... a total of 20,156,790 common shares of T-Bird (45% ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ... Drug Administration (FDA) has accepted its New Drug Application ... interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir ... treatment of adults with chronic genotype 4 (GT4) hepatitis ... the first all-oral, interferon-free therapy being evaluated by the ...
Breaking Medicine Technology:Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... 25, 2015 For thirteen years, the Twin ... protection education event in the nation! This year, on May ... Group, US to take DI Day on the road by ... Davidson, CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer at ... reflects on the change by stating, "The first Twin Cities ...
(Date:4/24/2015)... New York, NY (PRWEB) April 24, 2015 ... upscale sober living residence in Westchester County. Just 35 ... to help transition individuals back into everyday life while ... for Thursday, May 7, 2015, will allow therapists, doctors ... living areas and learn more about the opportunities offered ...
(Date:4/24/2015)... As the nation recognizes the Month of the ... young men and women, the “Alaska – Forget Me ... presents a special training session on Adverse Childhood Experiences ... understanding of the effect of childhood trauma and, in ... and military – who provide services and support to ...
(Date:4/24/2015)... April 24, 2015 Carvers' goal ... have a successful biking day in Breck. , ... five minutes walking distance from Breckenridge, this family-owned ... in both Breckenridge bike rentals ( http://www.breckenridgeskishop.com/en/rent-equipment ) ... offer extensive bike rentals in May 2015. With ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Lipitor ... forward in the federal multidistrict litigation underway in ... to court documents, the parties involved in the ... 16th detailing, among other things, preparation for the ... counsel for both plaintiffs and defendants have conducted ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Takes DI Day On The Road 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Carvers Breckenridge Bike Rentals Offers Demo Mountain, Tandem, Bike Path Cruiser & JR. Bikes in May 2015 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... Silicone breast implants went through a long period of relative dormancy ... Now, two years after the U.S. Food and Drug Administration approved ... plastic surgeon Richard L. Zeff, MD comments on why he feels ... ...
... Corticon offers special pricing on patent-pending Dialogs, the premier platform ... ... Redwood City, CA (PRWEB) April 2, ... in model-driven Business Rules Management Systems (BRMS), today announced special ...
... Nurse Training, Inc., provider of nurse training seminars on DVD and online ... ... April 2, 2009 -- Medical Nurse Training, Inc., provider of nurse training ... its website., , ,Medical Nurse Training, Inc. provides DVD and online courses ...
... IT, a national provider of medical documentation services and software, announced ... innovative medical documentation company that serves more than 450 healthcare professionals ... ... (PRWEB) April 2, 2009 -- MD IT , a national ...
... pregnancy, such as morning sickness, fatigue and weight gain, but despite this, ... Gurgle, we offer a guide to women in their early stages of ... ... (PRWEB) April 2, 2009 -- Around half of all women will experience ...
... April 2 In the first,quarter of 2009 (December ... figure of EUR237.3m (Q1 2008: EUR239.1m) almost at the ... world economy. In,the core business, however, sales by the ... The operating result (adjusted EBITDA) ...
Cached Medicine News:Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 2Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 3Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 4Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 2Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 3Health News:Medical Nurse Training, Inc. Announces the Launch of Medicalnursetraining.com 2Health News:MD IT Expands in the Northwest with Acquisition of Seattle's Pro Scribe 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 4Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 5Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 2Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 3Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 4
Adjustable speed vortex with inter-changeable heads , 110 V...
Adjustable speed vortex with inter-changeable heads, 110 V...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Vacuum Controller V-800 and water-cooled secondary condenser ... Compact Housing Model V-500 is a ... most vacuum applications. Applications Ideally ... evaporators Laboratory vacuum source for instruments ...
Medicine Products: